Kiniksa director trades shares under 10b5-1 plan

Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in February 2026 under a pre‑arranged Rule 10b5‑1 trading plan executed on September 11, 2025.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in February 2026 under a pre‑arranged Rule 10b5‑1 trading plan executed on September 11, 2025.

On February 10 and February 12, Barry exercised share options at an exercise price of $15.47 per Class A ordinary share and immediately sold the resulting shares in open-market transactions at $45 per share. Across both dates, 2,800 Class A ordinary shares were sold while maintaining 12,546 Class A ordinary shares held directly after the reported transactions. The options involved were fully vested and exercisable.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Quart Barry D

Role Director

Sold 2,800 shs ($126K)

Approx. gross sale proceeds $126K

Approx. exercise cost $43K

Type	Security	Shares	Price	Value
Exercise	Share Option	2,690	$0.00	$0.00
Exercise	Class A Ordinary Share	2,690	$15.47	$42K
Sale	Class A Ordinary Share	2,690	$45.00	$121K
Exercise	Share Option	110	$0.00	$0.00
Exercise	Class A Ordinary Share	110	$15.47	$2K
Sale	Class A Ordinary Share	110	$45.00	$5K

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 12,546 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
2. F2. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KNSA director Quart Barry D report?

Director Quart Barry D exercised options and sold Kiniksa Class A ordinary shares. He exercised options at $15.47 per share and sold 2,800 shares at $45 per share in open-market trades, all under a pre-arranged Rule 10b5-1 trading plan.

How many KNSA shares did the director sell and at what price?

Quart Barry D sold 2,800 Kiniksa Class A ordinary shares. The sales occurred in open-market or private transactions at a price of $45 per share, following the exercise of fully vested options with a $15.47 exercise price on two February 2026 dates.

How many KNSA shares does Quart Barry D hold after these trades?

After the reported transactions, Quart Barry D beneficially owns 12,546 Kiniksa Class A ordinary shares directly. This figure reflects his holdings following the February 10 and February 12, 2026 option exercises and related share sales disclosed in the Form 4 filing.

What options did the KNSA director exercise in February 2026?

The director exercised share options for 2,800 Kiniksa Class A ordinary shares. These options had an exercise price of $15.47 per share, were fully vested and exercisable, and are scheduled to expire on May 28, 2029, according to the derivative securities table.

Were KNSA director trades made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan. This plan was executed by the reporting person on September 11, 2025, providing a pre-arranged framework for the option exercises and subsequent share sales reported.

What is the relationship of the reporting person to KNSA?

The reporting person, Quart Barry D, is identified as a director of Kiniksa Pharmaceuticals International, plc. The Form 4 indicates he is not a 10% owner or officer, and the reported transactions involve his direct beneficial ownership of Class A ordinary shares and options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quart Barry D

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L, PLC

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	02/10/2026		M(1)		110	A	$15.47	12,656	D
Class A Ordinary Share	02/10/2026		S(1)		110	D	$45	12,546	D
Class A Ordinary Share	02/12/2026		M(1)		2,690	A	$15.47	15,236	D
Class A Ordinary Share	02/12/2026		S(1)		2,690	D	$45	12,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$15.47	02/10/2026		M(1)			110	(2)	05/28/2029	Class A Ordinary Shares	110	$0	2,690	D
Share Option	$15.47	02/12/2026		M(1)			2,690	(2)	05/28/2029	Class A Ordinary Shares	2,690	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.

2. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.